The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.

Neurooncol Adv · 2022 · PMC9000300 · PMID 35419519

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.0560

boldest claim

The sentences

highly significantP < .001actually significant

The univariate HR for OS of the development of new lesions was highly significant (HR = 5.27, P < .001) and increased after correction for other variables in a multivariate analysis (HR = 7.03, P < .001).

also in 132,142 other papers

borderline significantP = .056so close (0.05 < p ≤ 0.1)

HRs were borderline significant at ≥40% (HR = 1.76, P = .056) and not significant at ≥20% increase at first follow-up; at second follow-up the highest significant HR was found with the ≥20% increase threshold (HR = 10.70, P < .001).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.